Monthly Archives: April 2017

CTRMA Director Mike Heiligenstein Discusses Desperation of TX Infrastructure

Recently, the well known head of the CTRMA (the Central Texas Regional Mobility Authority), Mike Heiligenstein participated in a large scale transportation forum. The forum was constructed as a Q & A with the first question for the former Round Rock City council member and county commissioner being largely confined to the future fate of toll roads in Texas at large.

More specifically, the questioner notes that State Highway 130 has been through a two fold credit downsizing due to low traffic and wonders why so few Texans are driving on 130?

Mike Heiligenstein notes that the case of state highway 130 is a very peculiar one and that the first and main thing to understand is that the situation is nearly insurmountable within the expected timeframes (usually somewhere in the ballpark of 20 years or so).

The reason for this is that interstate 35 runs through geographically vexing areas such as the Colorado River which makes building extra lanes a utter impossibility. Coupled with the geographic challenges is the human element – very, very few cities wish to allow large lanes (whether vertically or horizontally) to be built in or through their districts. Learn more about Mike Heiligenstein: http://www.mobilityauthority.com/about/

Last, but certainly not least, the vast majority of traffic which many of the major areas in Texas, such as Austin and San Antonio, receive is local or regional traffic, not out of state. What this means is that even if new and more versatile lanes were built there still would not be much improvement due to the fact that the behavioral patterns of the drivers would still be the same.

What really needs to change, according to Mr. Heiligenstein is, not just the modality of the roads nor the lane capacity but also the travel behavior itself which can be modified through certain built in incentives.

Tim Amour’s Perspective On Mr. Buffett’s Investment Strategy

Mr. Buffett was right when he said that many common costly funds in the market shortchange investors. Firms should offer simple, low-cost investments for customers to buy and hold for the long term. Mr. Buffett’s bottom-up investing approach of meticulously scrutinizing companies and growing a steady portfolio has worked over the decades. In his latest yearly shareholder communication, Buffett highlights sound wisdom from his long-term investing.

Here’s Tim’s modest perspective on the same.

Too many investment funds offer low-quality returns on invested capital because of extreme trading and bloated management fees. In this regard, customers should shy away from fancy product labels. The industry’s active vs. passive argument does not serve shareholders interests. The risk factors of index investments are purely speculative. Experienced hedge fund managers don’t dwell on the active or passive aspect. It’s about producing quality long-term capital returns. You can never go wrong with low-cost investments that offer future higher yields.

Index funds deliver significant returns, but they do not cushion investors against losing markets. They expose clients to 100 percent risk and massive losses during market recessions. But markets evolve. Low profile funds perform better than crowded ones in bad times. An essential strategy a serious investor can do is to nurture their portfolio.

Tim’s Outlook on Asset Selloff in September 2015
Global stocks plummeted in the middle of investor anxiety about the slow economic development in China. A sharp decline in the Asian country’s stocks and a shocking currency deflation further stoked fears that China is crumbling. Tim Amor’s views on the china’s unfolding woes reflect on the US successive gains in the last six years. Other countries experienced the same market bullish effect.

Tim Armour implores that The U.S. markets valuations were extended for some industries and companies. The market correction was not expected. An occasional correction is good for the markets as it eliminates pockets of surplus.

Education and work background
Tim graduated with a B.A honors in economics from Middlebury College in Vermont. He currently works at Capital group and has a total 34years of investment fund management with Capital Group.

Reference: https://www.americanfunds.com/individual/news/senior-management-changes.html

Understanding Chronic Obstructive Pulmonary Disease and Stem Cell Treatment

The American Lung Association says that about 11 million people in the United States are suffering from the chronic obstructive pulmonary disease (COPD). However, it is unfortunate that about 24 million people have the disease but are not aware. COPD is a progressive lung disease that gives patients hard time breathing. There are two types of COPD, which are chronic bronchitis and emphysema. Most people suffering from COPD have a combination of both types. COPD causes the following changes in airways and lungs:

  • Mucus clogs the airways
  • The walls of air sacs get destroyed
  • The air sacs and airways are not able to stretch anymore
  • The walls of airways get inflamed and become thickened

The above changes cause a reduction of the amount of air flowing in and out of the lungs. It deprives the body the much oxygen required, which makes it harder for patients to breathe. COPD has no cure. However, research shows that stem cells therapy is being used to treat patients with this lung disease.

COPD and stem cell treatment

Stem cells are present in the adult lung. Stem cells in the lungs were discovered just recently; therefore, there is no stem cell treatment for COPD patients, http://www.hawaiinewsnow.com/story/33635903/copd-patients-are-saying-yes-to-stem-cells-at-the-lung-institute-in-tampa. However, researchers say that stem cell therapy is a promising option for COPD treatment research. Researchers have a vision of using stem cells to generate new and healthy lungs in patients with chronic lung disease. Some of the ways stem cells will benefit COPD patients include:

  • The cells stimulate the formation of new capillaries, which lead to enhanced lung function. The capillaries are small blood vessels present in lungs
  • The cells reduce swelling in the airways, which play a significant role in preventing further damage
  • The stem cells build new and healthy lung tissues, which have the ability to replace damaged tissues in the lungs.

About Lung Institute

The Lung Institute is a leading, innovative leader in regenerative medicine focusing on offering stem cell therapies for lung disease. The Institute is committed to offering patients an effective way of dealing with pulmonary conditions to improve their lives. The Lung Institute has treated more than 2000 patients, with 82% reporting an improvement in their lives, http://www.prweb.com/releases/2016/11/prweb13867190.htm .

The Lung Institute screens patients thoroughly to ensure best treatment results. They recognize that all patients require the best treatment. It has clinics in Dallas, Nashville, Texas, and Scottsdale.

For more info, visit the Lung Institute’s Facebook page and official website at lunginstitute.com.

Clay Siegall Is Creating Solutions For Cancer Patients

Dr. Clay Siegall has been working for years to try to create effective cancer treatments for individuals that are not responding well to other methods of treatment. He is the CEO of Seattle Genetics. Seattle Genetics is the largest cancer treatment production facility in the Northwest. So far Seattle Genetics has proven that they are one of the fastest growing companies in the market. Their stock prices have tripled in just the last five years.

In addition to serving as the CEO of Seattle Genetics, Dr. Clay Siegall also serves as the Chairman of the Board. He has held the title of CEO since 2002 but the company was founded in 1998. His company has been successful in developing cutting edge cancer therapy drugs and has more in the works.

Dr. Clay Siegall attended George Washington University where he obtained his Ph.D. He worked with prestigious pharmaceutical companies such as Bristol-Myers Squibb and the National Cancer Institute. The biggest accomplishment that Seattle Genetics has had with therapy drugs is Adcetris. Adcetris was approved in 2011 and is currently available in over sixty countries worldwide.

Dr. Clay Siegall has a passion for creating effective cancer treatments that can help patients when other treatments are ineffective. He combines his keen sense of business with his in-depth scientific knowledge to propel the company to new heights. He has a unique combination of talents that allow him to be highly successful and create good business strategies for Seattle Genetics. He has been able to raise over $1.2 billion from both public and private companies to help further fund research and development.

Securing the Gold Standard

According to an article posted by PR Newswire, over 650 executives from around the globe gathered at Caesar’s Palace Las Vegas Nevada on February 24th,2017 for the 11th annual Stevie Awards which also organizes other prestigious awards such as the International Business Award and the American Business Award.

Upon reading the article I discovered that Securus Technologies, a leading provider of civil and criminal justice technology solutions was awarded the Gold Stevie award for Best Customer Training Department; the article adds further illustration to the prestige of the award with a quote from Michael Gallegher President, and founder of the Stevie awards “The Stevie Awards for Sales & Customer Service continues to be among the most competitive and fastest-growing of our awards programs.” Securus Technologies was also given praise in the article from judges that participated in the naming of the winners that would take home gold; the compliments ranged from the importance of the role Securus plays in society to the improvements the company accomplished in customer survey results. If we consider that there were over 2,300 nominations from different organizations and industries globally, I find being a finalist to be impressive, to say the least.

In closing, I would like to highlight the use of the word “empathy” in a quote by Danny de Hoyos, Senior Vice President of Operation at Securus Technologies, to briefly paraphrase him, he emphasized the importance of recognizing the customers needs and situations, and empathy being an integral tool in connecting with customers; I found that strategy unique, seeing as how empathy historically has a mercurial value in the world of business, perhaps other companies would do well to follow the shimmering gold course plotted by Securus Technologies.